Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label dose-escalation study of GEN3013 in relapsed or refractory B-cell lymphoma
2023-504802-12-00Phase 2Authorised
- Sponsor
- Genmab
- Start
- May 2018
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 2, open-label trial of epcoritamab in malignant B-cell neoplasm and B-cell non-Hodgkin lymphoma (B-NHL) (3 arms), sponsored by Genmab. Planned start May 2018; status: authorised.
02
Drugs
epcoritamab
03
Conditions
malignant B-cell neoplasmB-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on 2023-504802-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504802-12-00.